Therefore, further understanding of OXPHOS regulation in AML helps us identify key therapeutic vulnerabilities, as exemplified by B cell lymphoma 2 (BCL2) inhibition, which works in part by regulating OXPHOS (Lagadinou Eleni et al., 2013; Pollyea et al., 2018). Here, BCL2 is linked to acute myeloid leukemia.